参考文献

[1]Vincent JL,De Backer D.Circulatory shock.N Engl JMed,2013,369(18):1726-1734.

[2]Cecconi M,De Backer D,Antonelli M,et al.Consensus on circulatory shock and hemodynamic monitoring.Task force of the European Society of Intensive Care Medicine.Intensive Care Med,2014,40(12):1795-1815.

[3]Singer M,Deutschman CS,Seymour CW,et al.The Third International Consensus Definitions for Sepsis and Septic Shock(Sepsis-3).JAMA,2016,315(8):801-810.

[4]Seymour CW,RosengartMR.Septic Shock:Advances in Diagnosis and Treatment.JAMA,2015,314(7):708-717.

[5]Shankar-Hari M,Phillips GS,Levy ML,et al.Developing a New Definition and Assessing New Clinical Criteria for Septic Shock:For the Third International Consensus Definitions for Sepsis and Septic Shock(Sepsis-3).JAMA,2016,315(8):775-787.

[6]Seymour CW,Liu VX,Iwashyna TJ,et al.Assessment of Clinical Criteria for Sepsis:For the Third International Consensus Definitions for Sepsis and Septic Shock(Sepsis-3).JAMA,2016,315(8):762-774.

[7]Abraham E.New Definitions for Sepsis and Septic Shock:Continuing Evolution but With Much Still to Be Done.JAMA,2016,315(8):757-759.

[8]Jacob JA.New Sepsis Diagnostic Guidelines Shift Focus to Organ Dysfunction.JAMA.2016,315(8):739-740.

[9]Rhodes A,Evans LE,AlhazzaniW,et al.Surviving Sepsis Campaign:International Guidelines for Management of Sepsis and Septic Shock:2016.Crit Care Med,2017,Jan 17.doi:10.1097/CCM.0000000000002255.[Epub ahead of print].

[10]Berry M,Patel BV,Brett SJ.New Consensus Definitions for Sepsis and Septic Shock:Implications for Treatment Strategies and Drug Development?Drugs,2017,Feb 10.doi:10.1007/s40265-017-0698-0.[Epub ahead of print].

[11]Perner A,Gordon AC,De Backer D,et al.Sepsis:frontiers in diagnosis,resuscitation and antibiotic therapy.Intensive Care Med,2016,42(12):1958-1969.

[12]McConnell KW,Coopersmith CM.Pathophysiology of septic shock:from bench to bedside.Presse Med,2016,45(4 pt2):e93-98.

[13]Hosseinian L,Weiner M,Levin MA,et al.Methylene Blue:Magic Bullet for Vasoplegia?Anesth Analg,2016,122(1):194-201.

[14]Lo JC,Darracq MA,Clark RF.A review of methylene blue treatment for cardiovascular collapse.J Emerg Med,2014,46(5):670-679.

[15]Paciullo CA,McMahon Horner D,et al.Methylene blue for the treatment of septic shock.Pharmacotherapy,2010,30(7):702-715.

[16]Schlesinger JJ,Burger CF.Methylene Blue for Acute Septic Cardiomyopathy in a Burned Patient.J Burn Care Res,2016,37(3):e287-291.

[17]Jang DH,Nelson LS,Hoffman RS.Methylene blue for distributive shock:a potential new use of an old antidote.JMed Toxicol,2013,9(3):242-249.

[18]Clifton J 2nd,Leikin JB.Methylene blue.Am JTher,2003,10(4):289-291.

[19]周训蓉,李江萍.亚甲蓝的化学、药理研究及临床应用进展.中国药业,2008,17(4):62-64.

[20]Kakihana Y,Ito T,Nakahara M,et al.Sepsis-induced myocardial dysfunction:pathophysiology and management.J Intensive Care,2016,4:22.

[21]Duan C,Yang G,Li T,et al.Advances in Vascular Hyporeactivity After Shock:The Mechanisms and Managements.Shock,44(6):524-534.

[22]De Backer D,Orbegozo Cortes D,Donadello K,etal.Pathophysiology of microcirculatory dysfunction and the pathogenesis of septic shock.Virulence,2014,5(1):73-79.

[23]Titheradge MA.Nitric oxide in septic shock.Biochim Biophys Acta,1999,1411(2-3):437-455.

[24]Levy B,Collin S,Sennoun N,et al.Vascular hyporesponsiveness to vasopressors in septic shock:from bench to bedside.Intensive Care Med,2010,36(12):2019-2029.

[25]Cauwels A,Brouckaert P.Nitrite regulation of shock.Cardiovasc Res,2011,89(3):553-559.

[26]Förstermann U,Sessa WC.Nitric oxide synthases:regulation and function.Eur Heart J,2012,33(7):829-837.

[27]López A,Lorente JA,Steingrub J,etal.Multiple-center,randomized,placebo controlled,double-blind study of the nitric oxide synthase inhibitor 546C88:effect on survival in patients with septic shock.Crit Care Med,2004,32(1):21-30.

[28]Kirov MY,Evgenov OV,Evgenov NV,et al.Infusion ofmethylene blue in human septic shock:a pilot,randomized,controlled study.Crit Care Med,2001,29(10):1860-1867.

[29]Memis D,Karamanlioglu B,Yuksel M,et al.The influence ofmethylene blue infusion on cytokine levels during severe sepsis.Anaesth Intensive Care,2002,30(6):755-762.

[30]Andresen M,Dougnac A,Díaz O,et al.Use of methylene blue in patients with refractory septic shock:impact on hemodynamics and gas exchange.JCrit Care,1998,13(4):164-168.

[31]Donati A,Conti G,Loggi S,et al.Does methylene blue administration to septic shock patients affect vascular permeability and blood volume?Crit Care Med,2002,30(10):2271-2277.

[32]Preiser JC,Lejeune P,Roman A,et al.Methylene blue administration in septic shock:a clinical trial.Crit Care Med,1995,23(2):259-264.

[33]Juffermans NP,VervloetMG,Daemen-Gubbels CR,etal.A dose-fnding study ofmethylene blue to inhibitnitric oxide actions in the hemodynamics of human septic shock.Nitric Oxide,2010,22(4):275-280.

[34]Fernandes D,SordiR,Pacheco LK,etal.Late,butnotearly,inhibition of soluble guanylate cyclase decreases mortality in a rat sepsismodel.JPharmacol Exp Ther,2009,328(3):991-999.

[35]Kwok ES,Howes D.Use of methylene blue in sepsis:a systematic review.J Intensive Care Med,2006,21(6):359-363.